WELL Health Technologies Corp. · TSX:WELL

WELL Health Technologies — Q3 2026 Earnings Presentation

22 slides from WELL Health Technologies's earnings presentation, Nov 9, 2026

  1. Slide 1: Q3-2026 Earnings Presentation

    Q3 - 2026 Earnings Presentation November 9, 2026

  2. Slide 2: Disclaimer

    Disclaimer Forward-Looking Information This presentation contains forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”) concerning WELL Health Technologies Corp. and its subsidiaries (“WELL H

  3. Slide 3: Today's Speakers

    Today’s Speakers Hamed Shahbazi Evelyn Sutherland Chief Executive Officer Chief Financial Officer 3

  4. Slide 4: Q3 Highlights

    Q3 Highlights A quarter of underlying earnings growth and strategic milestones HIGHLIGHTS: +20% Normalized Adjusted EBITDA1 growth 1. WELL Canadian Clinics Achieve Milestone of $100 Million Annualized Adjusted EBITDA Run-Rate 2. Completed WELLSTAR TSXV Listing, Eliminating $155M of 2026 GUIDANCE2 Pr

  5. Slide 5: WELL Q3-2026 Key Financial Highlights

    WELL Q3-2026 Key Financial Highlights1 Q3 Revenue Q3 Adj. EBITDA Q3 Adj. Sh. EBITDA $407.4M $50.9M $34.8M NORMALIZED Y/Y NORMALIZED Y/Y NORMALIZED Y/Y +17% +20% +13% Reported +12% Y/Y Reported −15% Y/Y Reported −19% Y/Y Q3 Adj. Gross Profit Q3 Adj. Gross Margin Q3 Adj. Net Income $177.8M 43.7% $27.3

  6. Slide 6: WELL Q3-2026 Operational Highlights

    WELL Q3-2026 Operational Highlights¹ $100M+ CANADIAN CLINICS Annualized Adjusted EBITDA run-rate achieved one quarter ahead of plan CANADIAN CLINIC PLATFORM 3,400+ 1.3M 179 Providers in WELL’s Canadian Patient visits in Canada Clinic Network Physical facilities² in Canada 1,500+ physicians in Canada

  7. Slide 7: Making a Positive Impact on Canadian Healthcare

    Making a Positive Impact on Canadian Healthcare Technology - enabled care is advancing patient engagement, clinical efficiency and patient experience across Canada. 84 520K+ 62K+ 120K+ NPS at WELL Clinics eReferrals Processed Patient Records Screened WELLTRUST Consents in Q3-2026 vs. 34 industry in

  8. Slide 8: OneWELL: One Integrated Platform to Address Canada's Healthcare Needs

    OneWELL: One Integrated Platform to Address Canada’s Healthcare Needs 01 02 03 Delivering Tech-enabling Population Health & AI connected care Providers TSX: WELL TSXV: WSTR TSX: AIDX ONE INTEGRATED STACK One partner across the health system – not a patchwork of point solutions. Primary Care Clinics

  9. Slide 9: Canada's Partner for Key Public Sector Priorities

    Canada’s Partner for Key Public Sector Priorities Provinces are prioritizing access, attachment, wait times and efficiency – OneWELL is built for this moment >$100M BC AB SK MB ON Engaged Contract Value1 QC NB NS PEI NL What Public Health is Solving for Why OneWELL Wins • Access: Timely care when an

  10. Slide 10: Strengthened Balance Sheet with $150M Bond Offering

    Strengthened Balance Sheet with $150M Bond Offering Extends debt maturity to 2031 and optimizes capital structure to support continued growth in Canada. $150M 6.875% 2031 July 15, 2026 Closed July 15 Senior Unsecured Coupon (per annum) Maturity (5-year Notes) Closed Early redemption of $70M converti

  11. Slide 11: WELLSTAR Listing: De-levering WELL and Unlocking Value

    WELLSTAR Listing: De-levering WELL and Unlocking Value Trading commenced October 1, 2026 (TSXV: WSTR), removing WELLSTAR’s ~$155M 1 of redeemable preferred shares from WELL’s balance sheet. ~$469M $93.0M +33% $83.7M Cash with No Debt or Q3-2026 YoY Revenue ARR4 in Q3-2026 (+27% Market Cap2 Preferred

  12. Slide 12: WELL YTD-2026 Canadian Clinics Financial Performance

    WELL YTD-2026 Canadian Clinics Financial Performance WELL Canadian Clinics WELL Canadian Clinics WELL Canadian Clinics Count1,2 Annual Revenue Growth Annual Adj. EBITDA Growth (C$ in 000s) (C$ in 000s) 350 500,000 70,000 302 450,000 300 60,000 400,000 250 350,000 50,000 300,000 200 40,000 250,000 15

  13. Slide 13: WELL Q3-2026 Canadian Clinics Financial Performance

    WELL Q3-2026 Canadian Clinics Financial Performance WELL Canadian Clinics WELL Canadian Clinics Q3-2026 Revenue1 Growth Q3-2026 Adj. EBITDA Growth (C$ in 000s) (C$ in 000s) 180,000 30,000 164,945 160,000 25,731 25,000 140,000 120,000 20,000 110,495 100,000 15,000 14,147 80,000 60,000 10,000 40,000 5

  14. Slide 14: WELL Providers Are Seeing More Patients

    WELL Providers Are Seeing More Patients WELL Canadian Clinics Billable Providers in WELL’s Patient Visits / Billable Provider Patient Visits1,2 Canadian Clinics Network2 Values in 000s 1,600 3,000 700 1,400 600 1,286 2,500 2,410 534 520 1,200 2,068 500 1,076 2,000 441 1,000 1,769 400 780 1,500 800 3

  15. Slide 15: Canadian Clinic Recent M&A Activity and Pipeline

    Canadian Clinic Recent M&A Activity and Pipeline Integration - focused Q3 - 2026 following an active first half of Canadian Clinic M&A YTD-2025 YTD-2026 +19 Clinics +27 Clinics 12 transactions 7 transactions +$67.0M +$102.0M Annual Revenue Annual Revenue +198 Providers +203 Providers Total Canadian

  16. Slide 16: Strategic Alternatives Processes for US Assets

    Strategic Alternatives Processes for US Assets 16

  17. Slide 17: Q3-2026 Financial Highlights: Revenue

    Q3-2026 Financial Highlights: Revenue Revenue bridge from Q3 - 2025 to Q3 - 2026 (C$ in 000,000s) 450.0 54.5 5.9 407.4 400.0 364.6 350.0 347.0 -17.6 300.0 250.0 200.0 150.0 100.0 50.0 0.0 1 Q3-25 Q3-25 CM Net Deferral Impact Normalized Q3-25 Canadian Clinics Other Revenue Q3-26 Increase Decrease Tot

  18. Slide 18: Q3-2026 Financial Highlights: Adjusted EBITDA

    Q3-2026 Financial Highlights: Adjusted EBITDA Adjusted EBITDA bridge from Q3 - 2025 to Q3 - 2026 (C$ in 000,000s) 70.0 59.9 60.0 11.6 50.9 50.0 -3.0 42.3 40.0 -17.6 30.0 20.0 10.0 0.0 1 Q3-25 Q3-25 CM Net Deferral Impact Normalized Q3-25 Canadian Clinics Corporate HQ and Other Q3-26 Increase Decreas

  19. Slide 19: Q3-2026 Financial Highlights: Adjusted Net Income

    Q3-2026 Financial Highlights: Adjusted Net Income1 Bridge from Net Income to Adjusted Net Income for Q3 - 2026 (C$ in 000,000s) 40 22.8 0.3 27.3 20 8.9 0 5.3 4.8 53.2 -20 -40 -60 67.5 -80 -100 -120 -140 -135.5 -160 Q3-26 Impairment Charge Costs Related to Early Settlement of Change in FV of Share-Ba

  20. Slide 20: Q3-2026 Financial Highlights: Adjusted FCF and FCFA2S

    Q3-2026 Financial Highlights: Adjusted FCF1 and FCFA2S2 Bridge from Adjusted EBITDA to FCF and FCFA2S for Q3 - 2026 (C$ in 000,000s) 60.0 50.9 50.0 -5.8 40.0 -9.8 30.0 25.6 -9.7 20.0 13.3 10.0 0.0 Cash Taxes Capex Q3-26 Adj. FCF Attributable to Q3-26 Adj. EBITDA Cash Interest Q3-26 Adj. FCF WELL Sha

  21. Slide 21: Updated Outlook

    Updated Outlook Disciplined Capital Allocation Program Driving Scale Canadian Updated 2026 Guidance1: + WELLSTAR Clinics Approx. $1.58B Revenue >$1 Billion Revenue3 $185-195M Adj. EBITDA run-rate by end of 2028 Sustained >10% Annual Expanding OneWELL as a Adj. EBITDA Growth² Partner to Public Sector

  22. Slide 22: Contact

    Contact Hamed Shahbazi CEO, Chairman & Founder hamed@well.company Evelyn Sutherland Chief Financial Officer evelyn.sutherland@well.company Pardeep Sangha Investor Relations investor@well.company www.well.company Vancouver, BC Canada 22 22

WELL Health Technologies — Q3 2026 Earnings Presentation on 6ix